CN104619845A - 联合治疗iii - Google Patents

联合治疗iii Download PDF

Info

Publication number
CN104619845A
CN104619845A CN201380047501.9A CN201380047501A CN104619845A CN 104619845 A CN104619845 A CN 104619845A CN 201380047501 A CN201380047501 A CN 201380047501A CN 104619845 A CN104619845 A CN 104619845A
Authority
CN
China
Prior art keywords
sirna
dna
artificial sequence
hdac4
reticent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380047501.9A
Other languages
English (en)
Chinese (zh)
Inventor
J.维斯特马克
A.考尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Turku
Original Assignee
University of Turku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Turku filed Critical University of Turku
Publication of CN104619845A publication Critical patent/CN104619845A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01098—Histone deacetylase (3.5.1.98), i.e. sirtuin deacetylase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380047501.9A 2012-07-13 2013-07-11 联合治疗iii Pending CN104619845A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20125795 2012-07-13
FI20125795 2012-07-13
PCT/FI2013/050745 WO2014009609A1 (en) 2012-07-13 2013-07-11 Combination therapy iii

Publications (1)

Publication Number Publication Date
CN104619845A true CN104619845A (zh) 2015-05-13

Family

ID=48917570

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380047501.9A Pending CN104619845A (zh) 2012-07-13 2013-07-11 联合治疗iii

Country Status (8)

Country Link
US (1) US10166241B2 (https=)
EP (1) EP2872631B1 (https=)
JP (1) JP6393682B2 (https=)
CN (1) CN104619845A (https=)
CA (1) CA2878873C (https=)
DK (1) DK2872631T3 (https=)
ES (1) ES2627500T3 (https=)
WO (1) WO2014009609A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106344923A (zh) * 2016-09-23 2017-01-25 中国人民解放军第二军医大学第二附属医院 组蛋白去乙酰化酶‑4抑制剂在制备治疗多发性骨髓瘤疾病药物中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077083A1 (en) * 2002-10-17 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase 4 expression
US20050112707A1 (en) * 1997-06-20 2005-05-26 Altaba Ariel R.I. Method and compositions for inhibiting tumorigenesis
CN1646558A (zh) * 2002-02-20 2005-07-27 吉田稔 组蛋白脱乙酰酶抑制剂及其制备方法
WO2006082448A1 (en) * 2005-02-07 2006-08-10 Topotarget Uk Limited Assays for agents with selective cytotoxicty to hdac resistant cell lines
CN101400362A (zh) * 2006-02-14 2009-04-01 哈佛大学校长及研究员协会 双官能组蛋白去乙酰化酶抑制剂
CN101610763A (zh) * 2006-12-15 2009-12-23 诺瓦提斯公司 杂环化合物及其使用方法
EP2197908A2 (en) * 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
CN101854804A (zh) * 2007-10-01 2010-10-06 利克斯特生物技术公司 Hdac抑制剂
CN101970399A (zh) * 2007-12-14 2011-02-09 乔治敦大学 组蛋白脱乙酰酶抑制剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133437A (en) 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
EP1135135A4 (en) * 1998-09-18 2006-08-09 Smithkline Beecham Corp CHK1 KINASE INHIBITORS
US6214986B1 (en) 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
WO2002081628A2 (en) 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
US20030190635A1 (en) 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
US20040019001A1 (en) 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
WO2004017991A1 (en) 2002-08-13 2004-03-04 Cell Center Cologne Gmbh Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin’s lymphomas
MXPA05003287A (es) 2002-09-28 2005-07-05 Massachusetts Inst Technology Influenza terapeutica.
US20040077084A1 (en) 2002-10-17 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase 4 expression
EP2305812A3 (en) 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
CA2523517C (en) 2003-04-25 2013-07-30 Dana-Farber Cancer Institute, Inc. Bcl2l12 polypeptide activators and inhibitors
US20050043266A1 (en) 2003-07-25 2005-02-24 Sumedha Jayasena Short interfering RNA as an antiviral agent for hepatitis C
WO2005011598A2 (en) 2003-07-31 2005-02-10 University Of South Florida Leukemia treatment method and composition
BRPI0413439A (pt) * 2003-08-08 2006-10-17 Novartis Ag combinações compreendendo estaurosporinas
MX2007001155A (es) 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
US20080021198A1 (en) 2005-10-12 2008-01-24 Yigong Shi Modulators of protein phosphatase 2A and PP2A methyl esterase
GB0612542D0 (en) 2006-06-23 2006-08-02 Novartis Ag Combinations comprising staurosporines
US20090274682A1 (en) 2008-02-05 2009-11-05 The Trustees Of Princeton University Demethylation and inactivation of protein phosphatase 2a
US20120130144A1 (en) 2009-02-04 2012-05-24 Bipar Sciences, Inc. Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112707A1 (en) * 1997-06-20 2005-05-26 Altaba Ariel R.I. Method and compositions for inhibiting tumorigenesis
CN1646558A (zh) * 2002-02-20 2005-07-27 吉田稔 组蛋白脱乙酰酶抑制剂及其制备方法
US20040077083A1 (en) * 2002-10-17 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase 4 expression
WO2006082448A1 (en) * 2005-02-07 2006-08-10 Topotarget Uk Limited Assays for agents with selective cytotoxicty to hdac resistant cell lines
CN101400362A (zh) * 2006-02-14 2009-04-01 哈佛大学校长及研究员协会 双官能组蛋白去乙酰化酶抑制剂
CN101610763A (zh) * 2006-12-15 2009-12-23 诺瓦提斯公司 杂环化合物及其使用方法
EP2197908A2 (en) * 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
CN101854804A (zh) * 2007-10-01 2010-10-06 利克斯特生物技术公司 Hdac抑制剂
CN101970399A (zh) * 2007-12-14 2011-02-09 乔治敦大学 组蛋白脱乙酰酶抑制剂

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D MOTTET ET AL.: "HDAC4 represses p21WAF1/Cip1 expression in human cancer cells through a Sp1-dependent, p53-independent mechanism，", 《ONCOGENE》 *
E.A. STRONACH ET AL.: "HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer", 《CANCER RESEARCH》 *
H. GENG ET AL.: "HDAC4 Protein Regulates HIF1 Protein Lysine Acetylation and Cancer Cell Response to Hypoxia", 《JOURNAL OF BIOLOGICAL CHEMISTRY》 *
LAURA R. SAUNDERS AND ERIC VERDIN: "Polyamines regulate sensitivity to HDAC inhibitor-induced apoptosis", 《CANCER RESEARCH》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106344923A (zh) * 2016-09-23 2017-01-25 中国人民解放军第二军医大学第二附属医院 组蛋白去乙酰化酶‑4抑制剂在制备治疗多发性骨髓瘤疾病药物中的应用
CN106344923B (zh) * 2016-09-23 2019-09-27 中国人民解放军第二军医大学第二附属医院 组蛋白去乙酰化酶-4抑制剂在制备治疗多发性骨髓瘤疾病药物中的应用

Also Published As

Publication number Publication date
US10166241B2 (en) 2019-01-01
CA2878873A1 (en) 2014-01-16
JP6393682B2 (ja) 2018-09-19
CA2878873C (en) 2018-08-21
JP2015527316A (ja) 2015-09-17
US20150209369A1 (en) 2015-07-30
EP2872631A1 (en) 2015-05-20
EP2872631B1 (en) 2017-05-03
WO2014009609A1 (en) 2014-01-16
DK2872631T3 (en) 2017-06-12
ES2627500T3 (es) 2017-07-28

Similar Documents

Publication Publication Date Title
CN103917228B (zh) 用于治疗过度增生性障碍、优选具有受损的p53功能的过度增生性障碍的包含CIP2A沉默剂的药物组合
CN103555722B (zh) 利用不对称双链rna特异性抑制kras的方法和组合物
ES2708944T3 (es) Composiciones y métodos para la inhibición específica de la expresión de genes por DSRNA que tenga modificaciones
CN104968785A (zh) 用于通过双链RNA特异性抑制myc的方法和组合物
EP2723450B1 (en) Combination therapy
CN108367022A (zh) 具有高活性和降低脱靶的sirna结构
EP2872631B1 (en) Combination therapy
US10094834B2 (en) Method of selecting individualized brain cancer therapy
JP2009513112A (ja) アラビノース修飾ヌクレオチドを含む低分子干渉リボ核酸二重鎖
WO2012100172A2 (en) Methods and compositions for the specific inhibition of hif-1a by double stranded rna
TWI715594B (zh) 用於麩胱甘肽Ｓ轉移酶Ｐｉ（ＧＳＴ－π）基因調控之ＲＮＡ干擾劑

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20201211